Cargando…

1431. Comparison of Treatment Outcomes with Definitive Antibiotic Therapy and Empiric Antibiotic Therapy in Osteomyelitis

BACKGROUND: Definitive therapy for osteomyelitis (OM) is thought to be superior to empiric antimicrobial therapy; however, identifying causative pathogens is difficult. METHODS: This retrospective cohort study included patients treated with either definitive or empiric antimicrobial therapy for OM a...

Descripción completa

Detalles Bibliográficos
Autores principales: Holzum, Dorothy, Pearson, Christopher D, Moenster, Ryan P, Linneman, Travis W, McMahan, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809601/
http://dx.doi.org/10.1093/ofid/ofz360.1295
_version_ 1783462028937003008
author Holzum, Dorothy
Pearson, Christopher D
Moenster, Ryan P
Linneman, Travis W
McMahan, Jonathan
author_facet Holzum, Dorothy
Pearson, Christopher D
Moenster, Ryan P
Linneman, Travis W
McMahan, Jonathan
author_sort Holzum, Dorothy
collection PubMed
description BACKGROUND: Definitive therapy for osteomyelitis (OM) is thought to be superior to empiric antimicrobial therapy; however, identifying causative pathogens is difficult. METHODS: This retrospective cohort study included patients treated with either definitive or empiric antimicrobial therapy for OM at VA St. Louis HCS between 1 January 2010 and 1 January 2018. Definitive antibiotic therapy was defined as a regimen tailored to susceptibilities of an organism(s) cultured from bone or deep tissue. The primary outcome was treatment failure, defined as a need for unplanned surgical intervention or re-initiation of antibiotic therapy for OM of the same anatomical site within 6-months after initial therapy was discontinued. Secondary outcomes included the incidence of acute kidney injury (AKI), Clostridium difficile-associated diarrhea (CDAD), and thrombocytopenia. Surgical intervention as part of initial therapy, presence of peripheral vascular disease (PVD), creatinine clearance < 50 mL/minute at initiation of therapy, receiving antibiotics at an extended care facility, age > 60 years, and receiving definitive antibiotics were included in a univariate analysis with variables with a P < 0.2 included in a multivariate logistic regression. RESULTS: There were 301 patients included; 179 in the definitive therapy group and 122 in the empiric therapy group. Baseline characteristics were similar among groups; however, more patients receiving definitive therapy had a bone biopsy compared with those treated with empiric therapy (58.1% (104/179) vs. 36.8% (45/122); P < 0.05). 33 percent (60/179) of patient treated with definitive therapy failed compared with 45% (55/122) treated with empiric therapy (P = 0.109). No significant differences were observed in secondary outcomes; however non-CDAD diarrhea occurred more in the empiric therapy group than definitive therapy group (3.9% (7/179) vs. 8.2% (10/122); P > 0.05). Receiving definitive therapy (OR 1.43, CI 0.89–2.313; P = 0.138) and presence of PVD (OR 1.34; CI 0.823–2.197; P = 0.238) were included in the multivariate logistic regression, but neither were independently associated with failure. CONCLUSION: Definitive antibiotic therapy was not associated with a significant decrease in treatment failure. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6809601
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68096012019-10-28 1431. Comparison of Treatment Outcomes with Definitive Antibiotic Therapy and Empiric Antibiotic Therapy in Osteomyelitis Holzum, Dorothy Pearson, Christopher D Moenster, Ryan P Linneman, Travis W McMahan, Jonathan Open Forum Infect Dis Abstracts BACKGROUND: Definitive therapy for osteomyelitis (OM) is thought to be superior to empiric antimicrobial therapy; however, identifying causative pathogens is difficult. METHODS: This retrospective cohort study included patients treated with either definitive or empiric antimicrobial therapy for OM at VA St. Louis HCS between 1 January 2010 and 1 January 2018. Definitive antibiotic therapy was defined as a regimen tailored to susceptibilities of an organism(s) cultured from bone or deep tissue. The primary outcome was treatment failure, defined as a need for unplanned surgical intervention or re-initiation of antibiotic therapy for OM of the same anatomical site within 6-months after initial therapy was discontinued. Secondary outcomes included the incidence of acute kidney injury (AKI), Clostridium difficile-associated diarrhea (CDAD), and thrombocytopenia. Surgical intervention as part of initial therapy, presence of peripheral vascular disease (PVD), creatinine clearance < 50 mL/minute at initiation of therapy, receiving antibiotics at an extended care facility, age > 60 years, and receiving definitive antibiotics were included in a univariate analysis with variables with a P < 0.2 included in a multivariate logistic regression. RESULTS: There were 301 patients included; 179 in the definitive therapy group and 122 in the empiric therapy group. Baseline characteristics were similar among groups; however, more patients receiving definitive therapy had a bone biopsy compared with those treated with empiric therapy (58.1% (104/179) vs. 36.8% (45/122); P < 0.05). 33 percent (60/179) of patient treated with definitive therapy failed compared with 45% (55/122) treated with empiric therapy (P = 0.109). No significant differences were observed in secondary outcomes; however non-CDAD diarrhea occurred more in the empiric therapy group than definitive therapy group (3.9% (7/179) vs. 8.2% (10/122); P > 0.05). Receiving definitive therapy (OR 1.43, CI 0.89–2.313; P = 0.138) and presence of PVD (OR 1.34; CI 0.823–2.197; P = 0.238) were included in the multivariate logistic regression, but neither were independently associated with failure. CONCLUSION: Definitive antibiotic therapy was not associated with a significant decrease in treatment failure. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809601/ http://dx.doi.org/10.1093/ofid/ofz360.1295 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Holzum, Dorothy
Pearson, Christopher D
Moenster, Ryan P
Linneman, Travis W
McMahan, Jonathan
1431. Comparison of Treatment Outcomes with Definitive Antibiotic Therapy and Empiric Antibiotic Therapy in Osteomyelitis
title 1431. Comparison of Treatment Outcomes with Definitive Antibiotic Therapy and Empiric Antibiotic Therapy in Osteomyelitis
title_full 1431. Comparison of Treatment Outcomes with Definitive Antibiotic Therapy and Empiric Antibiotic Therapy in Osteomyelitis
title_fullStr 1431. Comparison of Treatment Outcomes with Definitive Antibiotic Therapy and Empiric Antibiotic Therapy in Osteomyelitis
title_full_unstemmed 1431. Comparison of Treatment Outcomes with Definitive Antibiotic Therapy and Empiric Antibiotic Therapy in Osteomyelitis
title_short 1431. Comparison of Treatment Outcomes with Definitive Antibiotic Therapy and Empiric Antibiotic Therapy in Osteomyelitis
title_sort 1431. comparison of treatment outcomes with definitive antibiotic therapy and empiric antibiotic therapy in osteomyelitis
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809601/
http://dx.doi.org/10.1093/ofid/ofz360.1295
work_keys_str_mv AT holzumdorothy 1431comparisonoftreatmentoutcomeswithdefinitiveantibiotictherapyandempiricantibiotictherapyinosteomyelitis
AT pearsonchristopherd 1431comparisonoftreatmentoutcomeswithdefinitiveantibiotictherapyandempiricantibiotictherapyinosteomyelitis
AT moensterryanp 1431comparisonoftreatmentoutcomeswithdefinitiveantibiotictherapyandempiricantibiotictherapyinosteomyelitis
AT linnemantravisw 1431comparisonoftreatmentoutcomeswithdefinitiveantibiotictherapyandempiricantibiotictherapyinosteomyelitis
AT mcmahanjonathan 1431comparisonoftreatmentoutcomeswithdefinitiveantibiotictherapyandempiricantibiotictherapyinosteomyelitis